Evidence map›Paper›PMID 34404828›Full record

ArticleScientific reports2021

Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes.

Emma S Scott, Andrzej S Januszewski, Luke M Carroll, Gregory R Fulcher, Mugdha V Joglekar, Anandwardhan A Hardikar, Timothy W Jones, Elizabeth A Davis, Alicia J Jenkins

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Emma S ScottNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Andrzej S JanuszewskiNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Luke M CarrollNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Gregory R FulcherDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Mugdha V JoglekarNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Anandwardhan A HardikarNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Timothy W JonesUniversity of Western Australia, Perth, Australia.
Elizabeth A DavisUniversity of Western Australia, Perth, Australia.
Alicia J JenkinsNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. alicia.jenkins@ctc.usyd.edu.au.
National Health and Medical Research Council · AUNorthern Sydney Local Health District · AUPrincess Margaret Hospital for Children · AUSt Vincent's Hospital · AUUniversity of Melbourne · AUUniversity of Sydney · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519-563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. - 2.2 ± - 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.

Indexed as

AdolescentBlood GlucoseChildDiabetes Mellitus, Type 1FemaleGene Expression RegulationHumansHypoglycemic AgentsInjections, SubcutaneousInsulinMaleMicroRNAsBlood GlucoseHypoglycemic AgentsInsulinMicroRNAs

Identifiers

PMID34404828
PMCPMC8370996
OpenAlexW3194624494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.